|
Brigatinib monotherapy in children with R/R ALK+ ALCL, IMT, or other solid tumors: Results from the BrigaPED (ITCC-098) phase 1 study. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Takeda (Inst) |
|
Maaike Boonstra-Schelfhorst |
Research Funding - Takeda (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Roche/Genentech; Servier |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Natasha K.A. van Eijkelenburg |
|
|
|
Travel, Accommodations, Expenses - SERVIER |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Amgen; AstraZeneca; Takeda |
|
|
No Relationships to Disclose |
|
|
|
|
|
Other Relationship - Development of study Briga-Ped (IIT) with input from Takeda |
|
|
Consulting or Advisory Role - Abbvie (Inst); Gilead Sciences (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst) |
Research Funding - Abbvie/Genentech (Inst); Daiichi Sankyo (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Pfizer (Inst); Takeda (Inst) |
|
|
Research Funding - Takeda (Inst) |